Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Gastrointestinal Stromal Tumors 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia 2Burkitt Lymphoma 2Squamous Cell Carcinoma of Head and Neck 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Neoplasms 1Neoplasm, Residual 1Myeloproliferative Disorders 1Melanoma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid 1Leukemia, Biphenotypic, Acute 1Hypereosinophilic Syndrome 1Hematologic Diseases 1Head and Neck Neoplasms 1Digestive System Neoplasms 1Congenital Bone Marrow Failure Syndromes 1Blast Crisis 1

Interventions

nilotinib 2asciminib 2fludarabine 1bosutinib 1Imatinib Mesylate 1Dasatinib 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Philadelphia Chromosome × Imatinib Mesylate × 90 days × Clear all
NCT04971226 2026-06-05

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Novartis

Phase 3 Active not recruiting
405 enrolled 18 charts 1 FDA
MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡